 The MTOR signaling pathway has been found to be involved in many diseases such as cancer, arthritis, insulin resistance, and osteoporosis. It is also implicated in cellular processes such as cell proliferation, autophagy, and apoptosis. Recently, several new MTOR inhibitors have been developed for use in clinical trials, and it has been observed that these compounds can work synergistically with existing treatments. This review discusses the role of MTOR in chymorrhogesis and its potential as a therapeutic target. This article was authored by Jilin Zhu, Tao Tao, Hong Mei Li, and others.